MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

January 31, 2025 Metsera hits $2.7 bln valuation as ... drug frenzy Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss ...

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

In February, Solid Biosciences announced promising initial data from ... Sionna went public in February, and six insiders decided to take part in the offering by buying a total of around $62. ...

Metsera also closed its initial public offering in February 2025, generating gross proceeds of $316.2 million and aggregate net proceeds of $288.4 million. Metsera outlined its plans to utilize its ...

(Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial ...